Logo of Genetic Signatures (ASX:GSS)Latest Genetic Signatures (ASX:GSS) News

Page 1
Page 1 of 4

Genetic Signatures abandons Microba merger after funding concerns

Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.
Ada Torres
18 Nov 2026

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

BCAL challenges Genetic Signatures merger process before Takeovers Panel

Genetic Signatures’ proposed Microba merger faces a formal challenge from 18.46% shareholder BCAL Diagnostics, which alleges the process lacks adequate protections and information for GSS investors. The Takeovers Panel has not yet appointed a sitting Panel or decided whether to open proceedings.
Ada Torres
13 Nov 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Genetic Signatures puts revised Microba merger to shareholders

Genetic Signatures has added a new AGM resolution seeking approval to issue up to 340.7 million shares and 129.7 million options under its proposed Microba merger. The all-scrip transaction remains non-binding and subject to further shareholder, court, regulatory and due diligence conditions.
Ada Torres
23 Oct 2026

Genetic Signatures resets Microba merger split in favour of existing shareholders

Genetic Signatures and Microba Life Sciences have agreed in principle to revise their proposed merger, reducing Microba shareholders’ post-deal ownership from about 67% to 60%. The change improves the position of existing GSS shareholders, but the transaction remains non-binding and subject to multiple approvals.
Victor Sage
21 Oct 2026

Market Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Small-cap shares swung widely as exploration results, takeover bids and funding needs drove the week’s biggest moves.
Kaoko plunged while PARKD rallied, showing how quickly thinly traded stocks can change direction.
Logan Eniac
17 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Genetic Signatures warns board may resign if BCAL wins control

Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.
Ada Torres
16 Oct 2026

Market Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Exploration stocks dominated the biggest weekly moves, while several companies warned that cash, debt or approvals could decide what happens next.
Alvo Minerals led the market after heavy rare earth results, but company announcements remained a mixed source of confidence and concern.
Logan Eniac
10 Oct 2026

Healthcare Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Cynata led the week after launching a small capital raising, while Vitasora and Neurizon posted strong gains despite very different risks. Across healthcare, trial progress and regulator feedback competed with cash warnings and weaker share prices after trading gaps.
Logan Eniac
10 Oct 2026

Genetic Signatures cuts cash burn as Microba merger and board fight reshape outlook

Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.
Ada Torres
8 Oct 2026